Page 4 - Processa Pharmaceuticals News Today

Processa Pharmaceuticals, Inc. (PCSA) announced that after the meeting with the FDA, it has decided to expand the development of Next Generation Capecitabine or NGC-Cap into the treatment of advanced or metastatic breast cancer beginning with its next Phase 2 trial.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Friday. The Dow traded up 0.41% to 37,621.27 while the NASDAQ rose 0.66% to 15,154.43. The S&P 500 also rose, gaining, 0.46% to 4,803.12.

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 1% on Thursday. The Dow traded down 0.02% to 37,257.79 while the NASDAQ rose 1.19% to 15,032.26. The S&P 500 also rose, gaining, 0.49% to 4,762.36.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.35% to 37,398.50 while the NASDAQ rose 1.16% to 15,027.63. The S&P 500 also rose, gaining, 0.67% to 4,770.73.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 303,000 shares, a decrease of 17.6% from the November 30th total of 367,800 shares. Based on an average daily volume of 2,400,000 shares, […]

(MENAFN - Investor Brand Network) Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve ... ...

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...

Maxim Group reissued their hold rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a research note issued to investors on Friday, Benzinga reports. Processa Pharmaceuticals Stock Performance Shares of PCSA stock opened at $0.42 on Friday. The stock has a market cap of $10.46 million, a price-to-earnings ratio of -0.37 and a […]

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report)‘s stock had its “hold” rating reissued by investment analysts at Maxim Group in a note issued to investors on Friday, Benzinga reports. Processa Pharmaceuticals Trading Up 1.0 % Shares of NASDAQ PCSA traded up $0.00 during midday trading on Friday, reaching $0.42. 476,549 shares of the company were […]